Cargando…
Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032242/ https://www.ncbi.nlm.nih.gov/pubmed/36949080 http://dx.doi.org/10.1038/s41467-023-37338-7 |
| _version_ | 1784910755311648768 |
|---|---|
| author | Canetti, Michal Barda, Noam Gilboa, Mayan Indenbaum, Victoria Mandelboim, Michal Gonen, Tal Asraf, Keren Weiss-Ottolenghi, Yael Amit, Sharon Doolman, Ram Mendelson, Ella Harats, Dror Freedman, Laurence S. Kreiss, Yitshak Lustig, Yaniv Regev-Yochay, Gili |
| author_facet | Canetti, Michal Barda, Noam Gilboa, Mayan Indenbaum, Victoria Mandelboim, Michal Gonen, Tal Asraf, Keren Weiss-Ottolenghi, Yael Amit, Sharon Doolman, Ram Mendelson, Ella Harats, Dror Freedman, Laurence S. Kreiss, Yitshak Lustig, Yaniv Regev-Yochay, Gili |
| author_sort | Canetti, Michal |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10032242 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100322422023-03-23 Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up Canetti, Michal Barda, Noam Gilboa, Mayan Indenbaum, Victoria Mandelboim, Michal Gonen, Tal Asraf, Keren Weiss-Ottolenghi, Yael Amit, Sharon Doolman, Ram Mendelson, Ella Harats, Dror Freedman, Laurence S. Kreiss, Yitshak Lustig, Yaniv Regev-Yochay, Gili Nat Commun Author Correction Nature Publishing Group UK 2023-03-22 /pmc/articles/PMC10032242/ /pubmed/36949080 http://dx.doi.org/10.1038/s41467-023-37338-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Author Correction Canetti, Michal Barda, Noam Gilboa, Mayan Indenbaum, Victoria Mandelboim, Michal Gonen, Tal Asraf, Keren Weiss-Ottolenghi, Yael Amit, Sharon Doolman, Ram Mendelson, Ella Harats, Dror Freedman, Laurence S. Kreiss, Yitshak Lustig, Yaniv Regev-Yochay, Gili Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up |
| title | Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up |
| title_full | Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up |
| title_fullStr | Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up |
| title_full_unstemmed | Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up |
| title_short | Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up |
| title_sort | author correction: immunogenicity and efficacy of fourth bnt162b2 and mrna1273 covid-19 vaccine doses; three months follow-up |
| topic | Author Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032242/ https://www.ncbi.nlm.nih.gov/pubmed/36949080 http://dx.doi.org/10.1038/s41467-023-37338-7 |
| work_keys_str_mv | AT canettimichal authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT bardanoam authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT gilboamayan authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT indenbaumvictoria authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT mandelboimmichal authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT gonental authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT asrafkeren authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT weissottolenghiyael authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT amitsharon authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT doolmanram authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT mendelsonella authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT haratsdror authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT freedmanlaurences authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT kreissyitshak authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT lustigyaniv authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup AT regevyochaygili authorcorrectionimmunogenicityandefficacyoffourthbnt162b2andmrna1273covid19vaccinedosesthreemonthsfollowup |